A. Kantar, Woo-Jung Song, Andrew Bush, Grigorios Chatziparasidis
{"title":"Cough in Non-Cystic Fibrosis Bronchiectasis","authors":"A. Kantar, Woo-Jung Song, Andrew Bush, Grigorios Chatziparasidis","doi":"10.1183/23120541.00330-2024","DOIUrl":null,"url":null,"abstract":"Non-cystic fibrosis bronchiectasis (NCFBE) belongs to the spectrum of chronic suppurative lung diseases and is characterised by persistent wet/sputum-productive cough and airway dilatation. Morphological and structural changes in the airways lead to changes in airflow, impair breathing-induced mucus transport and sliding, and reduce the shear forces of cough. Moreover, mucus hyperviscosity contributes to compromised ciliary activity and the pathogenesis of the disease. This review highlights the role of cough in NCFBE, especially with respect to mucus clearance.Cough is the principal backup mechanism when mucus clearance is impaired due to either or both reduced function of cilia- and breathing-induced mucus transport, as well as abnormal mucus. The efficiency of cough in overcoming the cohesive and adhesive properties of mucus is determined by both the forces applied to mucus by airflow and the mucus-airway surface properties.In NCFBE, mucus hyperviscosity contributes to impaired mucus clearance and confers to disease pathogenesis; therefore, it may be a therapeutic target. The primary objectives of physiotherapy regimens in NCFBE are mucus hydration and the establishment of an optimal expiratory airflow velocity, which exerts shearing forces on the mucus located on the airway surface. Modifying the rheological properties of mucus and enhancing its transport whenever possible (by breathing manoeuvres, ciliary activity, and cough) represent prime goals in preventing disease progression and indeed reversing bronchiectasis in the early stages of the disease, as well as preventing pulmonary exacerbations.","PeriodicalId":504874,"journal":{"name":"ERJ Open Research","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ERJ Open Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1183/23120541.00330-2024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Non-cystic fibrosis bronchiectasis (NCFBE) belongs to the spectrum of chronic suppurative lung diseases and is characterised by persistent wet/sputum-productive cough and airway dilatation. Morphological and structural changes in the airways lead to changes in airflow, impair breathing-induced mucus transport and sliding, and reduce the shear forces of cough. Moreover, mucus hyperviscosity contributes to compromised ciliary activity and the pathogenesis of the disease. This review highlights the role of cough in NCFBE, especially with respect to mucus clearance.Cough is the principal backup mechanism when mucus clearance is impaired due to either or both reduced function of cilia- and breathing-induced mucus transport, as well as abnormal mucus. The efficiency of cough in overcoming the cohesive and adhesive properties of mucus is determined by both the forces applied to mucus by airflow and the mucus-airway surface properties.In NCFBE, mucus hyperviscosity contributes to impaired mucus clearance and confers to disease pathogenesis; therefore, it may be a therapeutic target. The primary objectives of physiotherapy regimens in NCFBE are mucus hydration and the establishment of an optimal expiratory airflow velocity, which exerts shearing forces on the mucus located on the airway surface. Modifying the rheological properties of mucus and enhancing its transport whenever possible (by breathing manoeuvres, ciliary activity, and cough) represent prime goals in preventing disease progression and indeed reversing bronchiectasis in the early stages of the disease, as well as preventing pulmonary exacerbations.